Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single ascending dose study of oral PHA-022121 in healthy adults
NL-OMON49665Phase 1Withdrawn
- Sponsor
- Pharvaris
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hereditary angioedema (HAE) comparing PHA-022121 with Placebo (2 arms). Primary endpoints: Safety and tolerability and PHA-022121 pharmacokinetics. Planned start Apr 2020; status: withdrawn.
02
Drugs
deucrictibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NL-OMON49665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49665.